{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02290041",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CeTMAd-VIH-2014"
      },
      "Organization": {
        "OrgFullName": "Andalusian Network for Design and Translation of Advanced Therapies",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response",
      "OfficialTitle": "Clinical Trial Phase I/II, of Test of Concept, Blind Double, Randomized, Controlled With Placebo, to Assess the Safety and Efficiency of the Treatment With Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue Expanded, in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 8, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 30, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 30, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "November 10, 2014",
      "StudyFirstSubmitQCDate": "November 12, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 13, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 3, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 4, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Iniciativa Andaluza en Terapias Avanzadas",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Phase I/IIClinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (MSCs: placebo), total sample size is 15 subjects",
      "DetailedDescription": "This is a phase I-II, randomised, placebo-controlled, clinical trial, currently ongoing in a single Spanish hospital (Hospital Virgen del Rocío, Seville), to evaluate the safety and feasibility of a 4-doses treatment regimen with MSCs (1 million cells/Kg MSCs, weeks 0-4-8-20) in HIV infected adults with swith discordant virological and immunological response to antiretroviral therapy. In the initial phase of the trial (n=5), patients were sequentially recruited, with a safety period of 15 days, receiving unblinded cell therapy. In the second phase of the trial, subjects are block randomised (1:1) to receive either MSCs (n=5), or placebo (n=5), as the control treatment. Immune response variables, adverse events, opportunistic infection signs are evaluated as determinants of safety and efficacy of MSCs. Study endpoints are measured along a follow-up period of 24 months, that includes 17 visits according to a decreasing frequency rate. Intention to treat, and per protocol, and safety analysis will be performed."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Discordant Immunological Response in HIV Infected Subjects"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "mesenchymal stem cells",
          "HIV Infection",
          "discordant immunological response"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Phase 1: uncontrolled, single arm biosafety evaluation (n=5) Phase 2: placebo-controlled, randomized, evaluation (n=10)",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "5",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Infusion of MSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Intravenous infusion of 4 doses of Placebo",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Infusion of placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Infusion of MSC",
            "InterventionDescription": "Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Infusion of placebo",
            "InterventionDescription": "Infusion of placebo (weeks 0-4-8-20)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of adverse reactions",
            "PrimaryOutcomeDescription": "Incidence of adverse reactions grade 3 and 4 according to DAIDs scale",
            "PrimaryOutcomeTimeFrame": "24 months"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence of opportunist diseases",
            "PrimaryOutcomeTimeFrame": "24 months"
          },
          {
            "PrimaryOutcomeMeasure": "Changes in CD4+ cell count and CD4+/CD8+ ratio",
            "PrimaryOutcomeDescription": "Changes in CD4+ cell count and CD4+/CD8+ ratio as measured by flow citometry",
            "PrimaryOutcomeTimeFrame": "28 days after the 4th infusion MSCs/placebo"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nConfirmed HIV infection\nAge> 18 years, both sexes\nIn treatment with antiretroviral therapy (ART)\nSustained HIV viral load <50 copies / ml for ≥ 1 years prior to study entry\nCD4 + cell count < 350/mL\nImmunological discordant response defined as: an increase <75 or <150 in CD4+ cell counts within one or two years of undetectable viraemia, respectively; or CD4 + cell count <350/mcl after 3 years of ART and undetectable viraemia (<50 copies/ml) ≥ 1 year\nWriten informed consent\nIn women of child bearing potential or her partners:commitment to use contraceptive method of proved efficiency throughout the duration of the clinical trial\n\nExclusion Criteria:\n\nPregnancy, breastfeeding, or refusal to the use of contraceptive methods\nOpportunistic infections in the last 12 months prior to study entry\nActive co-infection with hepatitis B virus/hepatitis C virus\nChild Pugh's scale stage C cirrhosis of the liver of any a aetiology\nPortal hypertension and / or hypersplenism of any aetiology\nMalignant neoplasia\nTreatment with steroids, immunomodulators, interferon, chemotherapy or any other medicinal product that could modify the number of CD4+ within the last 12 months prior to study entry\nConfirmed analytical 3 or 4 grade (AIDS Clinical Trials Group scale) abnormalities",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Luis F. López Cortés, MD",
            "OverallOfficialAffiliation": "Hospitales Universitarios Virgen del Rocío",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Virgen del Rocío University Hospital",
            "LocationCity": "Seville",
            "LocationZip": "41013",
            "LocationCountry": "Spain"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000014766",
            "ConditionMeshTerm": "Viremia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000007239",
            "ConditionAncestorTerm": "Infections"
          },
          {
            "ConditionAncestorId": "D000018805",
            "ConditionAncestorTerm": "Sepsis"
          },
          {
            "ConditionAncestorId": "D000018746",
            "ConditionAncestorTerm": "Systemic Inflammatory Response Syndrome"
          },
          {
            "ConditionAncestorId": "D000007249",
            "ConditionAncestorTerm": "Inflammation"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M17402",
            "ConditionBrowseLeafName": "HIV Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2674",
            "ConditionBrowseLeafName": "Acquired Immunodeficiency Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16663",
            "ConditionBrowseLeafName": "Viremia",
            "ConditionBrowseLeafAsFound": "Viremia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20017",
            "ConditionBrowseLeafName": "Sepsis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16021",
            "ConditionBrowseLeafName": "Toxemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19971",
            "ConditionBrowseLeafName": "Systemic Inflammatory Response Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9445",
            "ConditionBrowseLeafName": "Inflammation",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M186752",
            "InterventionBrowseLeafName": "Remestemcel-l",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}